Quidel

News Release

Printer Friendly Version View printer-friendly version << Back
June 26, 2007 at 7:02 AM EDT

Quidel Announces Appointment of Industry Veteran Richard C. Tarbox III as Senior Vice President, Corporate Development Officer

SAN DIEGO--(BUSINESS WIRE)--June 26, 2007--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care diagnostic tests, today announced the appointment of Richard C. Tarbox III, as its senior vice president, corporate development officer, effective July 16, 2007.

"The newly created SVP, corporate development officer position will report directly to my office, and reflects our commitment to continued leadership in rapid point-of-care testing," said Caren Mason, the Company's president and chief executive officer. "Ric will play an integral role in shaping and carrying out the strategic objectives for the Company and will also assume leadership of our Specialty Products Group (SPG). His extensive experience in managing and driving business growth will support achievement of our strategic objectives. We are delighted to secure the talents of such an accomplished professional."

Commenting on his appointment Mr. Tarbox said, "Quidel represents a unique opportunity due to the established reputation for high quality development, manufacturing and marketing of critical rapid diagnostic tests, to leverage that market position and achieve significant growth through appropriate industry alliances. I am looking forward to joining this strong leadership team and bringing my experience to bear during the next phase of Quidel's growth."

Mr. Tarbox has extensive experience as a business development professional with more than 30 years experience in the life sciences industry. Most recently, he held the position of vice president, strategic sourcing & business development for the Healthcare Market Division of Thermo Fisher Scientific Incorporated, where he was responsible for management of vendor relationships, strategic sourcing and M&A activity in the Healthcare sector.

Previously, Mr. Tarbox held senior operations and business development roles with Ostex International, Inc., Baxter International, Inc. and American Hospital Supply Corporation, among others. Mr. Tarbox is a graduate of the University of Washington where he received his Bachelor's Degree and the Kellogg School of Management at Northwestern University where he earned a Master's in Business Management. He has served on the boards of numerous organizations, including Ostex International, Inc., DenOptix, Inc., Metrika Laboratories, Inc., BioSeparations, Inc., and ClearData Communications, Inc., as well as serving as a Regent for Brophy College Preparatory in Phoenix, Ariz. and as a member of the Board of Directors for the British School in Bern, Switzerland.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point-of-care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, infectious mononucleosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com, www.colorectal-test.com or www.flutest.com.

This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, seasonality, the length and severity of cold and flu seasons, uncertainty surrounding the detection of novel influenza viruses involving human specimens, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, technological changes and uncertainty with research and technology development, including any future molecular-based technology, the reimbursement system currently in place and future changes to that system, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration (the "FDA"), intellectual property, product liability, environmental or other litigation, required patent license fee payments not currently reflected in our costs, potential inadequacy of booked reserves and possible impairment of goodwill, and lower than anticipated sales or market penetration of our new products. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision or update of the forward-looking statements.

CONTACT:
Quidel Corporation
John Radak, CFO, 858-552-7962
or
Lippert/Heilshorn & Associates
Don Markley/Bruce Voss, 310-691-7100

SOURCE: Quidel Corporation